The Elucigene TRP F Plus and PAI 1 kits
5 high risk mutations
Reliable and accurate detection
Simple, easy to use protocol
Venous thromboembolisms (occurs in 1-2 individuals per 1000 and there are approximately 10 million cases worldwide. There are between 100,000 and 300,000 VTE related deaths in the US, and 544,000 in Europe each year, which has resulted in a major health economic burden. There are many factors that increase the risk of thrombophilia such as surgery, pregnancy, the use of oral contraceptives and prolonged immobilisation (economy class syndrome)
Genetic factors also contribute to an individual’s risk of VTE Factor V Leiden is the most common inherited form of thrombophilia, occurring in 3.8% of the general US and European population in a heterozygous state. Heterozygous individuals are 7 fold more likely to develop a VTE, while homozygous individuals have an 80 fold increased risk Prothrombin thrombophilia is the second most common form and occurs in approximately 1 in 50 people in the Caucasian US and European population Mutations in MTHFR are associated with elevated homocysteine levels, an increased risk of blood clots, pregnancy loss or neural tube defects in offspring
The Elucigene Thrombophilia Range includes
TRP F plus : Factor V Leiden, Factor II, MTHR (677 C>T/1298 A>
PAI 1: 4G/5G
These kits offer detection of the five most relevant mutations implicated in an increased risk of developing venous thromboembolism
Benefits of the Elucigene Thrombophilia Range
Simple to use
Reagents ready to use in a single multiplexed tube –just add DNA
Minimal hands on time
Low failure rates
Rapid turnaround time
Easy to interpret
Optimally balanced primer
Test distinguishes between heterozygous and homozygous individuals
Assay validated on multiple thermal cyclers and ABI genetic analysers